Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-7-secreting Salmonella typhimurium
- Development stage
- Preclinical
- Lead developer
- Chungnam National University
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
IL-7-secreting Salmonella typhimurium is an attenuated strain of *Salmonella typhimurium* genetically engineered to express and secrete Interleukin-7 (IL-7). This microbial therapy utilizes an arabinose-inducible system to control the timing and level of cytokine secretion. By exploiting the natural tendency of *Salmonella* to accumulate within the hypoxic and immunosuppressive environment of solid tumors, the therapy delivers IL-7 locally to promote the survival, expansion, and activation of tumor-infiltrating T cells. Preclinical data indicate that this approach enhances the activity of cytotoxic CD8+ T cells and induces the formation of long-term antitumor immune memory, particularly when used in combination with immune checkpoint inhibitors like anti-PD-L1 antibodies.
- Other names
- IL-7-secreting SalmonellaIL7-secreting SalmonellaIL 7-secreting Salmonellaengineered Salmonella typhimurium secreting IL-7
02
Targets
IL7R (Interleukin-7 Receptor)
Beyond the preview
Go deeper on IL-7-secreting Salmonella typhimurium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-7-secreting Salmonella typhimurium.